Repligen Corporation (NasdaqGS:RGEN) in our automated value investing analysis, with the cash flow history and price comparison below.
Advertisement helps keep Trendshare free for most readers.
Estimate how long you need to hold Repligen Corporation to reach your target.
Based on historical returns, we believe that Repligen Corporation can grow its free cash at a rate of about 6%. That's positive!
| Advantages | Disadvantages | Neutral |
|---|---|---|
|
|
|
| RGEN Price (Repligen Corporation stock price per share) |
$170.29 | |
|
|
RGEN Fair Price (based on intrinsic value) |
$32.95 |
| RGEN Safety Price (based on a variable margin of safety) | $19.77 | |
|
Try your own return
The fair price above uses a 10.1% discount rate, the long-run US stock return (10.1% geometric, 1926 to 2025, from Bessembinder's working paper, updated 2026-11-09), and 2.5% terminal growth. A higher rate suits a higher return target and gives a lower value. Value per share: |
||
| PE Ratio versus Sector | 610% higher than other Healthcare stocks | |
| PE Ratio versus Industry | 149% higher than other Biotechnology stocks | |
| Free Cash Flow Jitter | 53% | |
In the six months to 2026-11-20, no insider bought shares, and 1 insider sold in 2 trades, about $186 thousand.
The six months before that had 0 buys and 3 sales.
Open-market buys and sells reported by Repligen Corporation's officers, directors, and 10% owners on SEC Form 4. Routine transactions (tax withholding, option exercises, and stock grants) are excluded -- these are discretionary trades only.
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-07-16 | Garland Jason K (CFO) | Sell | 530 | $150.00 |
| 2026-06-25 | Garland Jason K (CFO) | Sell | 733 | $145.00 |
| 2026-04-21 | Loeillot Olivier (Chief Executive Officer) | Sell | 3,832 | $140.00 |
| 2025-12-17 | DAWES KAREN A | Sell | 275 | $161.00 |
| 2025-11-25 | Loeillot Olivier (Chief Executive Officer) | Sell | 7,041 | $170.00 |
| 2025-11-18 | Bylund James (Chief Operating Officer) | Sell | 2,191 | $151.21 |
| 2025-11-13 | Hunt Anthony | Sell | 2,500 | $154.32 |
| 2025-11-13 | Hunt Anthony | Sell | 2,923 | $153.14 |
| 2025-11-13 | Hunt Anthony | Sell | 2,100 | $152.17 |
| 2025-11-13 | Hunt Anthony | Sell | 1,784 | $151.01 |
This stock has short interest! This means that people have shorted it.
Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.
As of the latest analysis, there are 7,054,160 shares shorted. With 60,962,151 shares available for purchase and an average trading volume over the past 10 trading days of 913,570, it would take at least 7.7 days for all of the short holders to cover their shorts.
Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth
How to read this: free cash flow in plain terms, free cash flow jitter.
Each year names the SEC filer that reported it, so a change of filer shows up here.
| Fiscal year | SEC filer (CIK) | Free cash flow (USD millions) |
|---|---|---|
| 2010 | 730272 | -3 |
| 2011 | 730272 | 2.7 |
| 2012 | 730272 | 12.6 |
| 2013 | 730272 | 24.2 |
| 2014 | 730272 | 15.9 |
| 2015 | 730272 | 12.1 |
| 2016 | 730272 | 3.8 |
| 2017 | 730272 | 12.9 |
| 2018 | 730272 | 27 |
| 2019 | 730272 | 58.9 |
| 2020 | 730272 | 50.4 |
| 2021 | 730272 | 94.2 |
| 2022 | 730272 | 131 |
| 2023 | 730272 | 68.1 |
| 2024 | 730272 | 128 |
| 2025 | 730272 | 69.9 |
Download the yearly data as CSV.
How to read this: what free cash flow is, why earnings matter.
Over the 13 fiscal years from 2010 to 2025 with positive net income, operating cash flow totaled $783 million against net income of $584 million, or 1.34 times. Net income was negative in 3 of the 16 years, and those years are left out of the ratio.
In 2025, capital expenditures were $23.5 million, 20.0% of operating cash flow of $117 million, which leaves an estimated $93.9 million after capex. Across the 15 years with reported capex, it averaged 32.6% of operating cash flow. This uses that year's own capital expenditures, not the five-year average behind the free cash flow table, so the two can differ.
| Fiscal year | Net income (USD millions) | Operating cash flow (USD millions) | Capital expenditures (USD millions) | Operating cash flow / net income |
|---|---|---|---|---|
| 2010 | -4.1 | -2.4 | 0.6 | n/a |
| 2011 | -1.6 | 3.2 | 0.5 | n/a |
| 2012 | 14.2 | 13.4 | 1.3 | 0.95 |
| 2013 | 16.1 | 25.9 | 4.6 | 1.61 |
| 2014 | 8.2 | 18.4 | 5.6 | 2.25 |
| 2015 | 9.3 | 15.1 | 2.6 | 1.61 |
| 2016 | 11.7 | 7.5 | 4.3 | 0.64 |
| 2017 | 28.4 | 17.5 | 5.5 | 0.62 |
| 2018 | 16.6 | 32.8 | 10.6 | 1.97 |
| 2019 | 21.4 | 67.2 | 18.5 | 3.14 |
| 2020 | 59.9 | 62.6 | 22.5 | 1.05 |
| 2021 | 128 | 119 | 67.1 | 0.93 |
| 2022 | 186 | 172 | 84.8 | 0.93 |
| 2023 | 35.6 | 114 | 36.2 | 3.20 |
| 2024 | -25.5 | 175 | 25.7 | n/a |
| 2025 | 48.9 | 117 | 23.5 | 2.40 |
How to read this: earnings and margins.
Revenue was $21 million in 2010 and $738 million in 2025, a compound annual growth rate of 26.8% over 15 years. The starting revenue was under 10% of the latest, so that rate comes from a small base and says little about recent growth.
Revenue rose 16.4% from 2024 to 2025.
Our estimated free cash flow was $69.9 million in 2025, 9.5% of revenue. In 2010 the estimated margin was negative 14.5%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.
| Fiscal year | Revenue (USD millions) | Estimated free cash flow (USD millions) | Estimated free cash flow / revenue |
|---|---|---|---|
| 2010 | 21 | -3 | -14.5% |
| 2011 | 27.3 | 2.7 | 9.8% |
| 2012 | 62.3 | 12.6 | 20.3% |
| 2013 | 68.2 | 24.2 | 35.5% |
| 2014 | 63.5 | 15.9 | 25.0% |
| 2015 | 83.5 | 12.1 | 14.5% |
| 2016 | 105 | 3.8 | 3.7% |
| 2017 | 141 | 12.9 | 9.1% |
| 2018 | 194 | 27 | 13.9% |
| 2019 | 270 | 58.9 | 21.8% |
| 2020 | 366 | 50.4 | 13.7% |
| 2021 | 671 | 94.2 | 14.0% |
| 2022 | 802 | 131 | 16.4% |
| 2023 | 632 | 68.1 | 10.8% |
| 2024 | 634 | 128 | 20.2% |
| 2025 | 738 | 69.9 | 9.5% |
How to read this: how debt and assets are compared, the current ratio.
In 2025, cash and equivalents were $566 million against total liabilities of $844 million, or 67.1% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.
Total liabilities were 28.6% of total assets in 2025, compared with 13.2% in 2011, an increase of 15.4 percentage points.
Stockholders equity was $2,106 million in 2025, compared with $66 million in 2011, a rise of 3091.7%.
Based on our estimated free cash flow, cash flow return on invested capital (CROIC) was 3.1% in 2025. Invested capital here is total assets less cash and current liabilities.
| Fiscal year | Total assets (USD millions) | Cash and equivalents (USD millions) | Total liabilities (USD millions) | Stockholders equity (USD millions) |
|---|---|---|---|---|
| 2011 | 76.1 | 11.2 | 10.1 | 66 |
| 2012 | 97 | 29.2 | 12.9 | 84.1 |
| 2013 | 119 | 39.8 | 34.5 | 84.1 |
| 2014 | 128 | 35.4 | 16.6 | 112 |
| 2015 | 146 | 54.1 | 23.5 | 123 |
| 2016 | 289 | 122 | 120 | 169 |
| 2017 | 744 | 174 | 152 | 592 |
| 2018 | 775 | 194 | 159 | 616 |
| 2019 | 1,400 | 528 | 340 | 1,060 |
| 2020 | 1,903 | 717 | 374 | 1,529 |
| 2021 | 2,358 | 604 | 608 | 1,750 |
| 2022 | 2,532 | 523 | 621 | 1,911 |
| 2023 | 2,831 | 751 | 866 | 1,965 |
| 2024 | 2,830 | 757 | 857 | 1,973 |
| 2025 | 2,950 | 566 | 844 | 2,106 |
Of the 16 fiscal years we can see for Repligen Corporation under its current filer, 15 show positive free cash flow.
At $170.29, the price is above our fair value estimate of $32.95 for Repligen Corporation.
Free cash flow from the first three years of data averaged $4.1 million, and from the last three $88.7 million: a sharp rise.
Year-to-year variability in free cash flow is volatile, measured at 53%.
Dividends are not in our data for Repligen Corporation.
These numbers change when new filings or prices arrive, so treat this page as a snapshot and check the company's own filings.
How to read this: the price to earnings ratio.
Its trailing P/E ratio is 610% above the average for stocks in the Healthcare sector.
Its trailing P/E ratio is 149% above the average for stocks in the Biotechnology industry.
A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.
These are companies in the Biotechnology industry, the ones closest in market capitalization to Repligen Corporation, limited to companies whose pages we publish. The figures come from our latest data for each company.
| Company | Market cap (USD millions) | P/E | Dividend yield | Cash yield | Price versus our estimate |
|---|---|---|---|---|---|
| Repligen Corporation (RGEN) | 10,886 | - | - | - | 417% above |
| Bio-Techne Corporation (TECH) | 11,420 | 66.7 | 0.3% | 1.4% | 91% above |
| Neurocrine Biosciences (NBIX) | 15,850 | 23.2 | - | - | 491% above |
| Biogen (BIIB) | 36,531 | 107.0 | - | 9.9% | 69% below |
| Amgen (AMGN) | 237,363 | 25.4 | 2.2% | 4.4% | 11% below |
Industry labels are approximate, and companies in one industry can run quite different businesses, so a peer may not be a close match.
Ratios on different fiscal calendars are not strictly comparable, and a trailing P/E can be distorted by one-time items.
Every fiscal year on this page is reported by one SEC filer, CIK 730272.
Each figure on this page comes from that filer.
How to read this: understanding investment risk.
Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.
Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.
The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.
This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.
Read the filings yourself: RGEN annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.
Advertisement supports free stock analysis content.
Does Repligen Corporation have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.
This example shows how we apply the Trendshare checklist to RGEN: earnings power, cash generation, valuation, and margin of safety.
We check: business quality, free cash flow, P/E, and margin of safety.
Most Popular Articles
What is Dollar Cost Averaging?
Benjamin Graham, Value Investor
How Do Tariffs Affect the Stock Market?
Precious Metals for Value Investors